Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

Authors Colombo GL, Altomare GF, Peris K, Martini P, Quarta G, Congedo M, Constanzo A, Di Cesare A, Lapucci E, Chimenti S

Published 11 April 2008 Volume 2008:4(2) Pages 559—568

DOI https://doi.org/10.2147/TCRM.S2740

GL Colombo1, GF Altomare2, K Peris3, P Martini4, G Quarta5, M Congedo5, A Costanzo6, A Di Cesare3, E Lapucci4, S Chimenti6

1S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 2Institute of Dermatology, IRCCS, O. Galeazzi, Milan, Italy; 3Department of Dermatology, University of L'Aquila, L'Aquila, Italy; 4Department of Dermatology, Ospedale di Lucca, Italy; 5Department of Dermatology, Ospedale Vito Fazzi – Lecce, Italy; 6Department of Dermatology, University of Rome Tor Vergata, Italy

Abstract: Psoriasis is a chronic inflammatory, immune-mediated skin disorder that affects 1.5–1.8 million people in Italy. The most common form of the disease is chronic plaque psoriasis, affecting about 90% of psoriasis patients, with about 20%–30% of them suffering from a moderate or severe condition. Little information is available about the economic impact of psoriasis in European countries. The primary objective of this study was to perform a cost-of-illness analysis of patients with moderate and severe plaque psoriasis in Italy. Therefore, direct, indirect costs, and intangible costs (quality of life – QoL) were assessed. In this national, multicenter, prospective, 3-month cost-of-illness study of moderate and severe plaque psoriasis, direct and indirect costs were assessed from the patient, third-party payer (National Health Service, NHS), and societal perspectives. From November 2003 to October 2004 consecutive patients were enrolled over a 1-year period, in order to minimize seasonal fluctuations in disease severity. 150 patients enrolled in 6 investigational sites in Italy, completed the study, and were eligible to be analyzed according to the study protocol. Intangible costs (QoL) were measured using SF36 and DLQI questionnaires. The mean total cost for psoriasis (average Psoriasis Area Severity Index [PASI] score 21.4), including direct and indirect items, was €8,371.61 per patient per year. The mean cost for patients with moderate disease (PASI ≤ 20) was €5,226.04, while the mean cost for patients with more severe disease (PASI > 20) was €11,434.40 per year. Disease heavily affected QoL measured using SF36, and the impairment was greater in patients affected by a more severe form of disease. Moderate and severe plaque psoriasis is associated with extremely high costs, which are related to disease severity. Data from this study show that the more severe plaque psoriasis, the higher the direct and indirect costs for its management. Direct costs are higher than indirect costs; hospitalization represents the most significant item, accounting for 30% of the total expenses. QoL in moderate and severe plaque psoriasis is low compared with the population at large, confirming the high impact of plaque psoriasis on QoL. The relatively high average annual costs per patient point to the need for a more efficient and long-term control of psoriasis.

Keywords: cost of illness, psoriasis, quality of life

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G

Therapeutics and Clinical Risk Management 2015, 11:1603-1612

Published Date: 19 October 2015

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C

Patient Related Outcome Measures 2015, 6:53-60

Published Date: 17 February 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

Colombo GL, Matteo SD, Antinori A, Medaglia M, Murachelli S, Rizzardini G

ClinicoEconomics and Outcomes Research 2013, 5:489-496

Published Date: 3 October 2013

A cost-of-illness study of spina bifida in Italy

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C

ClinicoEconomics and Outcomes Research 2013, 5:309-316

Published Date: 2 July 2013

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S

ClinicoEconomics and Outcomes Research 2012, 4:375-382

Published Date: 5 December 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Antidiabetic therapy in real practice: indicators for adherence and treatment cost

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV

Patient Preference and Adherence 2012, 6:653-661

Published Date: 14 September 2012

Burden of Crohn’s disease: economics and quality of life aspects in Italy

Benedini V, Caporaso N, Corazza GR, Rossi Z, Fornaciari G, Cottone M, Frosini G, Caruggi M, Ottolini C, Colombo GL

ClinicoEconomics and Outcomes Research 2012, 4:209-218

Published Date: 24 July 2012

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P

ClinicoEconomics and Outcomes Research 2011, 3:197-205

Published Date: 31 October 2011

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al

ClinicoEconomics and Outcomes Research 2011, 3:55-61

Published Date: 14 March 2011

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

ClinicoEconomics and Outcomes Research 2011, 3:37-46

Published Date: 15 February 2011

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo, Sergio Di Matteo, Ketty Peris, Maria Concetta Fargnoli, et al.

ClinicoEconomics and Outcomes Research 2009, 1:53-59

Published Date: 15 October 2009

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

Giorgio L Colombo, Mauro Caruggi, Chiara Ottolini, Aldo P Maggioni

Vascular Health and Risk Management 2008, 4:223-234

Published Date: 8 February 2008

Readers of this article also read:

Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine

Zhao K, Rong G, Guo C, Luo X, Kang H, Sun Y, Dai C, Wang X, Wang X, Jin Z, Cui S, Sun Q

International Journal of Nanomedicine 2015, 10:2895-2911

Published Date: 13 April 2015

Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

Roy K, Kanwar RK, Krishnakumar S, Cheung CH, Kanwar JR

International Journal of Nanomedicine 2015, 10:1019-1043

Published Date: 2 February 2015

Enhanced antidepressant-like effects of the macromolecule trefoil factor 3 by loading into negatively charged liposomes

Qin J, Yang X, Mi J, Wang J, Hou J, Shen T, Li Y, Wang B, Li X, Zhu W

International Journal of Nanomedicine 2014, 9:5247-5257

Published Date: 12 November 2014

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease

Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM

International Journal of Nanomedicine 2014, 9:2677-2687

Published Date: 27 May 2014

Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis

Yan C, Wu Y, Feng J, Chen W, Liu X, Hao P, Yang R, Zhang J, Lin B, Xu Y, Liu R

International Journal of Nanomedicine 2013, 8:245-255

Published Date: 11 January 2013

Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles

Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S, Tamar G, Shneor R, Guez D, Margel S, Mardor Y

International Journal of Nanomedicine 2011, 6:1595-1602

Published Date: 3 August 2011

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma

Khaldoun Almhanna, Philip A Philip

OncoTargets and Therapy 2009, 2:261-267

Published Date: 13 November 2009

Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization

Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté

Vascular Health and Risk Management 2009, 5:101-119

Published Date: 11 January 2009

Formoterol in the management of chronic obstructive pulmonary disease

Paschalis Steiropoulos, Argyris Tzouvelekis, Demosthenes Bouros

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:205-215

Published Date: 6 June 2008

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007